Gene: SLC35E3
Official Full Name: solute carrier family 35 member E3provided by HGNC
Gene Summary: Predicted to enable antiporter activity and nucleotide-sugar transmembrane transporter activity. Predicted to be involved in transmembrane transport. Predicted to be located in membrane. Predicted to be active in Golgi apparatus. [provided by Alliance of Genome Resources, Apr 2025]
Catalog Number | Product Name | Species | Gene | Passage ratio | Mycoplasma testing | Price |
---|---|---|---|---|---|---|
KO14022 | SLC35E3 Knockout cell line (HeLa) | Human | SLC35E3 | 1:3~1:6 | Negative | Online Inquiry |
KO14023 | SLC35E3 Knockout cell line (HCT 116) | Human | SLC35E3 | 1:2~1:4 | Negative | Online Inquiry |
KO14024 | SLC35E3 Knockout cell line (A549) | Human | SLC35E3 | 1:3~1:4 | Negative | Online Inquiry |
SLC35E3 Gene Knockout Cell Lines are advanced cellular models engineered to disrupt the SLC35E3 gene, which encodes a nucleotide sugar transporter involved in glycosylation pathways. This precise genetic modification allows researchers to investigate the functional roles of SLC35E3 in cellular processes such as growth, differentiation, and response to stress, providing invaluable insights into the underlying mechanisms of various diseases, including cancer and metabolic disorders.
The SLC35E3 gene knockout works through CRISPR-Cas9 technology, which facilitates targeted gene editing. This method ensures a high degree of specificity, allowing for the creation of stable cell lines that lack the SLC35E3 protein. This knockout effect enables the exploration of altered cellular behaviors resulting from the absence of this transporter, offering a robust platform for understanding the interplay between glycosylation and pathophysiological conditions.
The scientific importance of these cell lines extends to both fundamental research and clinical applications. Researchers can utilize SLC35E3 knockout cell lines in drug discovery, toxicology studies, and the development of biopharmaceuticals, enhancing the understanding of how glycosylation affects drug efficacy. Additionally, these cell lines are pivotal in elucidating the biochemical pathways that could be targeted for therapeutic intervention.
Compared to alternative methods, the SLC35E3 Gene Knockout Cell Lines provide a more accurate representation of physiological conditions since they allow for the study of SLC35E3's role in a controlled environment without the complications of heterogeneity found in whole organisms or tissues. Moreover, their stability and ease of use make them suitable for high-throughput screening, increasing the efficiency of experimental workflows.
For researchers and clinicians seeking to comprehend the complex roles of glycosylation in health and disease, SLC35E3 Gene Knockout Cell Lines offer a vital tool to advance their investigations. Our commitment to quality and innovation in biological products ensures that users receive unparalleled scientific resources tailored to meet the demands of cutting-edge research.
Please note that all services are for research use only. Not intended for any clinical use.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.